The health and Family Planning Commission requires that the price of the original research drug should be lowered firmly, or the price should be negotiated and unified by the state

Source: on November 11, 2013, asidak news agency, great wisdom, not only received a cold reception in the drug bidding rules of various regions, but also the national health and Family Planning Commission is planning a round of "cutting down" on its price On Thursday, a person familiar with the recent national bidding forum told reporters that the national health and Family Planning Commission showed clear support for the price reduction of original research drugs at the meeting Sun Zhigang, deputy director of the health and Family Planning Commission, made it clear at the meeting that the "super national treatment" of the original research drugs should be reduced, the original research drugs should compete with generic drugs on the same stage, and said that "if the price of the original research drugs cannot be reduced, the state will centralize and unify them, and the state will negotiate and even price them uniformly." In fact, in the first half of this year, the central government's attitude towards the price reduction of the original research drugs has begun to take shape The price department of the national development and Reform Commission has planned to guide the price reform of drug payment, and implemented equal reimbursement for the original research drugs and generic drugs That is to say, no matter the amount paid by medical insurance for the original research drugs or domestic generic drugs is the same, the expenses beyond the scope of medical insurance shall be borne by individuals For example, for drugs with the same generic name, foreign drugs are 50 yuan, domestic generic drugs are 20 yuan, while medical insurance only pays 10 yuan for this kind of drugs Not only that, this year's outbreak of GSK event is also seen as a signal of foreign original research drug price reduction The aforementioned bidding meeting also mentioned that foreign commercial bribery also shows that there is much room for price reduction of the original research drug.